{"name":"Immune Cell, Inc.","slug":"immune-cell-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ICAR19 CAR-T cells","genericName":"ICAR19 CAR-T cells","slug":"icar19-car-t-cells","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ICAR19 CAR-T cells","genericName":"ICAR19 CAR-T cells","slug":"icar19-car-t-cells","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOOUh5WFkzUWYwMDNPYjlaQWxwZ2p0LUlScEMteUFyS1puZFRHWFRoVERUOUJ0dXNaZXhORVhQcW5lZWdIYWNpTUh2dEhMN0FQR2RKWVhKMzNvMXlxOElZZ3U1d2J5Yi1vai1mdjN2cFRRTGZRcjdVWHhqWWU3ZkVnTDNvSTBENzNrTGkydGl3eEhTQQ?oc=5","date":"2026-02-20","type":"pipeline","source":"Pharma Voice","summary":"No one-trick pony in oncology, Merck’s cancer footprint is expanding - Pharma Voice","headline":"No one-trick pony in oncology, Merck’s cancer footprint is expanding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPN19hRGVGVW5NdUpWcWlkWElUZXZLM2ZDTkgzeVBObzltZGdFYWI4RzBqNWthOFBiQXdyREF1WlJFQ0IyUW42RVZhMmxHR1ltZU5CbUlnUUZkcklvQ3BmMnNmS09pQ0Q1QnV3eERaU0I0WlktWHJDcXBvd3p1bDJNajB0d1EtMFFFb25jbjNuVUJta1JidVZ2VFpWU1FRWGd4QWVR?oc=5","date":"2026-02-18","type":"patent","source":"Contract Pharma","summary":"Pluri Biotech Secures China Patent for Immune Cell Tech - Contract Pharma","headline":"Pluri Biotech Secures China Patent for Immune Cell Tech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTFA4MW1uWXFaMEZKWnVLS2Uxb3pDNDNWaGdKcEdOZk5DVGNkNC1MMW5YWnQ4aGtOUnN3NEVCUEdST01POVBVbWFTSHI3SW5sbzA5NnduUk1DX056eXJyMU5HTU12d9IBaEFVX3lxTE1RSTBaZ0FBWTZoWUVHZ05NUktLTmxwVFFxRFQwRDRCWWRRTUlxa2R1c3VlS2hwZU9KVmFIU2t6ZExqMmFHOHZEc3NCbjFrbnQzQjNYMWdHRXoxNlhUN201N0RIenh3b0Jz?oc=5","date":"2026-02-09","type":"pipeline","source":"BioInformant","summary":"Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering - BioInformant","headline":"Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSDBXZ243SnRELU9tTG5VZTBBaUFIQkVwVmJEYW42OGc5emVxOWVhSGlZcng5U1RDZE5IWUM5YUdYRE1VSDBpVFZxTW5iNUF0X29DSUlDa3RBaHpKRmhwODNuU1hlRmEyQzNDLU9VUlVYN29vb3dTZFl1T21FU2FWNXpGZklzS2hZQXNoV21KczXSAZYBQVVfeXFMTmdVSG5xdU5Qa2JKdFpoQWYyaHhkUkxfM1FUdmljWjc5Z2VZYkxxRzhsa0VmZWZXc2h1UWY4MFFibXlwbXplT0VBS2dITk5ya1oxVlRwN3JJUF9fOFkwQlZ5eHB1NmNwRWZQV0NvMVlmSDZka3laZlZTMjNaN1FXdWxiU0hUSC1XckpWb09qRGNVSDI3UXdR?oc=5","date":"2026-01-17","type":"pipeline","source":"BioInformant","summary":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide - BioInformant","headline":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPR1ZQUHFiMnY1bG5EMFNYcmdrQlVFT1ZoMTk1NzYwLTBfZnNSUEZ4UTduOEc4cUdGbi03cTR6cnBsWGoydE5fRnhOcG5JMDB5SXJNaDBBOWFNLUNScU50dElyY1dUVE52aUN3YkJwbWQ2N3lfN3QtVzZkVk1CbFpYaGEwand6S3EyX2lUdlNzcXFfeGJ6NkVJT2ZCNXNJTkFuZEktWDhoNHpYd2J4QzJBSldITjBZNFJHcTlkZFJkRkhyOXNXM01VVkdIRmh3UVEwa0NPR2VBMDExUHY1Wmc?oc=5","date":"2025-12-06","type":"pipeline","source":"Reuters","summary":"Regeneron's experimental therapy combo effective in untreated cancer patients - Reuters","headline":"Regeneron's experimental therapy combo effective in untreated cancer patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQRThoSE5oRWpsQzdDVEZrZEhHR0d0TnZwYXZNM3NhYkVzLVR4SWlYcXprQUVxd1EyTDdWSVljY2h1SGgyN0F4czFQbFBabk0wSUFDeWNPR2N6d2pUM3ZiVzJxbU11VXZpbENKbXZZVWtSV3o3clZZemFTb0JzTFljM2lkMDcyRXc?oc=5","date":"2025-12-01","type":"pipeline","source":"BioSpace","summary":"6 Companies Hanging On in Cell Therapy - BioSpace","headline":"6 Companies Hanging On in Cell Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxPYy1fclZNcHp2SWFUODZLaDVoZmRoUWZOdUxpV0pLZ0FIVnp0aHdPN1d5WUgwWlFpaF9aVjBDSFdGMHpNc0hydmxta3FwQkNLdVB6YUsxaElXd3FfOVhHNUN6QTVmSUUzQ3M2NkRkNU1rQ2trMjNEeHBaRnBkcThjc3RObWJuMUE3VG1uM0VQb1VReWV0VDd6UTVKdVI2MmRVcllNYkkxdkdyYTNFQ3lqWHRFN2pIa0JJMnotZWpKWUtnSTE2RVNOMGw1dzROR1YwcW9HWlhiNWtaYlFSTWpRNVhDcUdUajJ0RU01Rk1xeElRVWFEUmlvell0elRQNExQaWR5bDg3RUhfVXMxVFVnNXJqTHJzc1RpTmN0cW5NZldUcTFO?oc=5","date":"2025-11-07","type":"trial","source":"Business Wire","summary":"​​Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward the Clinic With New Financing and Leading Clinical Advisor - Business Wire","headline":"​​Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward the Clinic With New Financing and L","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOdXB5cXdKQUttX3FwelcyaG1tUHpIVm1UXzh2a0dFSlBpQ2d0MVFXTE0xb3FjZ3NRV2p1VnJ3bWhNU0RLSUM0Sk9LanZnR2I3bDZScWlCTTZqM0pGS25wRVR0YWpDOFRaV3FhaTk1eGo1UGlpUXR4cDRBRERaY2xoVHBTVkdYT2NNMWZCbllKRGhNcXVwTzVHQl94VndzdnQ5NURidzMwNWpVSHRzOXpBYTN1LVZ4UkhuZ3hvaHRZZnJyc2NMUGpaUVRn?oc=5","date":"2025-10-14","type":"deal","source":"European Pharmaceutical Review","summary":"Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn - European Pharmaceutical Review","headline":"Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPLTRoemFGeUh4b1RmYXV6WFFCWXhNMWNJQ3BxYXZ3RkJtejdQWjZ4elRUZ0RDaXBrNU5OZGQ2MjdqU25hbzlIMUJ0ZjlYbmNpZkJYcjJwYUFTa3c0cl8tX21VaFB6RVlZbThWcVNPUEZWVFpjTXFzU0JIUWhtc3dfdXdVdWNLelBGMDhMZURzV1lmZGNvZ2NBR0k3eHUzeVk?oc=5","date":"2025-10-08","type":"pipeline","source":"BioPharma Dive","summary":"Venture firms pour $101M into a biotech using the brain to fix the immune system - BioPharma Dive","headline":"Venture firms pour $101M into a biotech using the brain to fix the immune system","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOMGdMVXdiYVk4RjZ0bUF0YWlXUFpILVM5RU4zR21DMEY4ZGxHTnpKZHNKVmNyUkxvUTdZM0YyV0xSRkk2TGNIV0g4c1NVNlZRaUFmek54dnZWT0RraXFXcnJPa1BBQnNqYWdXLU9ZNU5xaFdqV0xGUDJoRlFUX3NqZVM3Mm81WjNwN2xDT1l5R0hwUm0tb1oyYmMtNmpnTGtVT1QzUVBLM0xLY21RUUg5Y2RMd1VPUTRzZTljMGJrRWJmUmNSR1E?oc=5","date":"2025-09-08","type":"patent","source":"PR Newswire","summary":"PhotonPharma Inc. Receives U.S. Patent for Innovative Cancer Immunotherapy - PR Newswire","headline":"PhotonPharma Inc. Receives U.S. Patent for Innovative Cancer Immunotherapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE0wZmVnR0FBNzJCRS04UzF3Rm1TM25Xa3hCN1plY0xETTdsSVRJNUdoWWNfMHlCUm1XUTZTaWw3ZGpqMGsyNWJoUGEyYXo3REZuelBXQ3FmekxWRVlhM2lfeTRUU2FXWDlKY21oOHVKSWtadw?oc=5","date":"2024-01-11","type":"pipeline","source":"Labiotech.eu","summary":"Ten NK cell therapy companies to look out for this year - Labiotech.eu","headline":"Ten NK cell therapy companies to look out for this year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNMXlWSjhyYTdGUDlfbEhpRmp0eDJUcHNnVlhoUm9Rc2JZWGtSRDlMRTdVaDhsSFdXZ21KMVVydzk2MGRDZzBqMklFdnBRdVpKMDlyb21LUVNKbG5kbUVJVWtMeHp2NllDQ3UyNklDaWp6TEtmTlQ5RXU1V09pbDY4R1hOODhSSTFfaUVBeG9jWnFla2lUOEZMZDJYMDVwc1NYYm1VTzljYWxLTmFnVGVJOVVabDY5UEhhMHhoS291eDJJZlE?oc=5","date":"2021-09-09","type":"pipeline","source":"Johns Hopkins Medicine","summary":"Right Program Could Turn Immune Cells into Cancer Killers - Johns Hopkins Medicine","headline":"Right Program Could Turn Immune Cells into Cancer Killers","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}